Brain cancer research briefing detailing a company's clinical development initiative and what to expect next from an early-stage therapeutic program.
Key Takeaways
- HDT Bio formed a Canadian subsidiary to advance cancer clinical development and manufacturing
- HDT-401 combines Riboxxim licensed from Riboxx with the LION nucleic acid delivery platform
- HDT completed a pre-CTA meeting with Health Canada and plans a McGill-led Phase 1 trial